Sanofi India credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Dec 2025FY25Dec 2024FY24Dec 2023FY23Dec 2022FY22 and earlierAlpha Plus
−275−275−295−405−1,017
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−0.37×−0.37×−0.34×−0.40×−0.80×
−0.54×−0.56×−0.60×−0.50×−1.44×
267.06×267.06×302.73×449.65×389.71×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SANOFI₹3,189.50

Sanofi India Limited

· Pharma & Health
₹ CrorePeersSENORESINNOVACAPPGHLMOREPENLABIOLCPSANOFICONRFDCORCHPHARMAMcap ₹7,336 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/12/2022
FY24
31/12/2023
FY25
31/12/2024
FY26
31/12/2025
Last 12M
30/09/2026
Net Debt-1,016.9-404.9-294.8-274.9-274.9
Net Debt/Equity-0.80-0.40-0.34-0.37-0.37
Net Debt/EBITDA-1.44-0.50-0.60-0.56-0.54
Interest Coverage (EBIT/Interest)389.71449.65302.73267.06267.06
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.